180 related articles for article (PubMed ID: 10393290)
1. New delivery systems and propellants.
Dolovich M
Can Respir J; 1999; 6(3):290-5. PubMed ID: 10393290
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical transition to non-CFC pressurized metered dose inhalers.
Cripps A; Riebe M; Schulze M; Woodhouse R
Respir Med; 2000 Jun; 94 Suppl B():S3-9. PubMed ID: 10919679
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol.
Fireman P; Prenner BM; Vincken W; Demedts M; Mol SJ; Cohen RM
Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808
[TBL] [Abstract][Full Text] [Related]
4. Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.
Bronsky E; Ekholm BP; Klinger NM; Colice GL
J Asthma; 1999; 36(1):107-14. PubMed ID: 10077140
[TBL] [Abstract][Full Text] [Related]
5. The technical transition to CFC-free inhalers.
Tansey I
Br J Clin Pract Suppl; 1997 May; 89():22-7. PubMed ID: 9519509
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting the efficiency of aerosol therapy with pressurised metered-dose inhalers through plastic spacers.
Chuffart AA; Sennhauser FH; Wildhaber JH;
Swiss Med Wkly; 2001 Jan; 131(1-2):14-8. PubMed ID: 11205181
[TBL] [Abstract][Full Text] [Related]
8. Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group.
Salat D; Popov D; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S22-8. PubMed ID: 10919682
[TBL] [Abstract][Full Text] [Related]
9. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology.
Acerbi D; Brambilla G; Kottakis I
Pulm Pharmacol Ther; 2007; 20(3):290-303. PubMed ID: 16890465
[TBL] [Abstract][Full Text] [Related]
10. [Changes in metered dose inhaler propellants].
Chinet T
Rev Mal Respir; 2000 Feb; 17(1):15-20. PubMed ID: 10756552
[TBL] [Abstract][Full Text] [Related]
11. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.
Kunka R; Andrews S; Pimazzoni M; Callejas S; Ziviani L; Squassante L; Daley-Yates PT
Respir Med; 2000 Jun; 94 Suppl B():S10-6. PubMed ID: 10919680
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
[TBL] [Abstract][Full Text] [Related]
13. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability.
Brindley A
J Allergy Clin Immunol; 1999 Dec; 104(6):S221-6. PubMed ID: 10588978
[TBL] [Abstract][Full Text] [Related]
14. Switching to CFC-free beclometasone for asthma.
Drug Ther Bull; 2008 Jun; 46(6):46-8. PubMed ID: 18525059
[TBL] [Abstract][Full Text] [Related]
15. Plume temperature emitted from metered dose inhalers.
Brambilla G; Church T; Lewis D; Meakin B
Int J Pharm; 2011 Feb; 405(1-2):9-15. PubMed ID: 21129465
[TBL] [Abstract][Full Text] [Related]
16. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system.
Ross DL; Gabrio BJ
J Aerosol Med; 1999; 12(3):151-60. PubMed ID: 10623331
[TBL] [Abstract][Full Text] [Related]
17. Developing an in vitro understanding of patient experience with hydrofluoroalkane-metered dose inhalers.
Doub WH; Shah V; Limb S; Guo C; Liu X; Ngo D
J Pharm Sci; 2014 Nov; 103(11):3648-3656. PubMed ID: 25228114
[TBL] [Abstract][Full Text] [Related]
18. The CFC to HFA transition and its impact on pulmonary drug development.
Leach CL
Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403
[TBL] [Abstract][Full Text] [Related]
19. The change to non-CFC metered dose inhalers.
Rubinfeld A
Aust Fam Physician; 1997 Dec; 26(12):1412-4. PubMed ID: 9470296
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
